PINNED
PINNED
Streamlining Biomanufacturing of Personalised Cancer Immunotherapies with Synthetic DNA
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
List view / Grid view
Articles
The promise of vectors targeting the LDL receptor
In this Q&A, Pascaline Lécorché, Head of Chemical Biology at Vect-Horus, outlines the potential of RNA interference therapeutics and the challenges of their use in vivo. There are several strategies to overcome these, and why peptide-based vectors targeting the LDL receptor are a promising approach.
Treating immune-mediated diseases with nanoparticles
In this Q&A, we had the privilege of speaking to COUR Pharmaceuticals’ CEO John Puisis. He offers insights into how their innovative immune-modifying nanoparticle platform differs from traditional approaches for treating immune-mediated diseases.
Women in Stem with Dr Rachel Lagiakos
Dr H. Rachel Lagiakos is a Senior Principal Scientist in the Therapeutics Group at Schrödinger which she joined in 2018. She completed her PhD in Synthetic Organic Chemistry at Monash University and began her medicinal chemistry career at Cancer Therapeutics (CTx) in Melbourne, Australia in 2012. At CTx, Rachel’s contributions…
Harnessing natural killer cells to combat age-related diseases
In this Q&A, Celularity’s CEO and founder Dr Robert Hariri details the preclinical research that indicates that placenta-derived unmodified NK cells and genetically modified NK cells can target and selectively eliminate cells expressing stress ligands.
Leveraging ADCs in precision oncology strategy
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.
Kickstarting the use of AI for biotechs: part two
Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch up with their AI-enabled peers – but why should they, and how? In this article – the second of a three-part series – Dr Raminderpal Singh touches on methods that are being…
Improving treatment responses to solid tumours with trispecific TCEs
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
Enhancing gene therapy with Circio
In this Q&A, Erik Wiklund, CEO of Circio, explains the key findings of their circVec circular RNA platform technology, why they chose AAV-based gene therapy for AATD as the lead programme, and their plans for the future to enhance the potency and reduce the cost of current gold-standard gene therapy.
Women in Stem with Vicky Marsh Durban
Join us for our Women in Stem series with Dr Vicky Marsh Durban, Director of Custom Organoid Services at Molecular Devices. Her highly successful career began with a PhD from Cardiff University in 2008 focusing on cancer genetics. She then completed a post-doctoral research scholarship at UCSF and a Research…
Transomics’ impact on a promising liver cancer therapeutic
Using its AI-driven platform, Pepper Bio discovered a promising therapeutic for liver cancer. In this Q&A session with Jon Hu, CEO and co-founder of Pepper Bio, we dive into how the identification of two inhibitors led to a $135M in-licensing deal.
A new era of genetic and mechanistic molecular neuroscience
Neuroscientists are increasingly viewing disorders of the brain through the lens of the underlying molecular mechanisms as sometimes illuminated by genetic variants, rather than classifying disorders based solely on the clinical symptoms. The next step in the evolution of antiseizure medication will likely come from studying these molecular determinants of…
The promise of therapeutics from molecules within our body
In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches.
Kickstarting the use of AI for biotechs: part one
Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch-up with their AI-enabled peers – but why should they, and how? In this article – the first of a three-part series – Dr Raminderpal Singh seeks to demystify the topic by outlining…
Utilising engineered peptides for immunotherapy
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
Overcoming the limitations of current drug discovery approaches
In this Q&A, Simon Kerry, CEO of Curve Therapeutics, shares the company’s recent milestones, insights into the innovative Microcycle platform, and how Curve plans to remain on the cutting edge of drug discovery.
